Candel Therapeutics Inc., a clinical-stage biopharmaceutical company specializing in multimodal biological immunotherapies for cancer, announced that it will present new data from its HSV-based platform and the linoserpaturev (CAN-3110) program in recurrent high-grade glioma (rHGG) at the 7th Annual Glioblastoma Drug Development Summit, scheduled for February 17-19, 2026, in Boston, Massachusetts. Francesca Barone, M.D., Ph.D., Chief Scientific Officer, will deliver presentations and participate in panel discussions focusing on biomarker-driven clinical development, patient stratification, and the integration of biomarkers and imaging in clinical trials. The results and insights from the study will be presented during the summit and have not yet been publicly disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9652379-en) on February 11, 2026, and is solely responsible for the information contained therein.